Young Eun Chon, Ju Hyun Shim, Joo Hyun Oh, Jiwon Yang, Hyunjae Shin, Wonseok Kang, Yeongseok Hwang, Su Jong Yu, Jongman Kim, Hae Won Lee, Yoon Jun Kim, Sook-Hyang Jeong
Clin Mol Hepatol 2025;31(4):1107-1114. Published online October 1, 2025
Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trial Hyunjae Shin, Youngsu Park, Byeong Geun Song, Won-Mook Choi, Hyung Joon Han, Youngwoo Lee, Tae-Jin Song, Jong-Eun Yeon, Young-Suk Lim, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Joon Hyeok Lee, Jung-Hwan Yoon, Jeong-Hoon Lee Cancer Immunology, Immunotherapy.2026;[Epub] CrossRef
Mendelian randomization (MR), a powerful statistical tool for causal inference, has been widely applied in various fields of medical research, even extending to economics and psychology. In hepatology, MR has been utilized to identify risk factors and potential therapeutic targets for liver diseases, including metabolic dysfunction-associated steatotic liver disease, cholestatic and autoimmune liver diseases, and hepatobiliary cancer. MR can provide evidence of causation via associations between genetic variants, modifiable exposures and liver disease occurrence or outcomes, using large existing datasets. However, results from MR studies are sometimes scattered, biologically not plausible or even controversial between analyses, potentially reflecting a trend of inappropriate application of this method (e.g., inappropriate selection of genetic instruments, insufficient assessment of horizontal pleiotropy, compromised statistical power, and neglected genetic diversity among different populations), and thus hinder the translation of MR findings from bench to bedside. Assessing these critical issues and pinpointing bona fide evidence are essential but quite challenging for clinicians. In this review, we aim to introduce the MR method to hepatologists and provide a comprehensive overview of the current MR findings that are relevant for hepatologists. Furthermore, we will discuss how to evaluate the quality of MR publications, interpret MR findings, and illustrate good practice of using MR studies in hepatology.
Citations
Citations to this article as recorded by
Childhood Obesity and Age‐Related Diseases: A Systematic Review and Meta‐Analysis of Mendelian Randomization Evidence Haoxue Zhu, Xinghao Yi, Mengyu He, Siyi Wu, Ming Li, Shan Gao Pediatric Obesity.2026;[Epub] CrossRef
Association of genetically instrumented HMGCR inhibition with the therapeutic role of prostate cancer: a Mendelian randomization study and supporting in vitro experiments Xiaojie Hao, Jingjun Mu Frontiers in Pharmacology.2026;[Epub] CrossRef
Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis Juhee Ahn, Moon Haeng Hur, Hyunjae Shin, Min Kyung Park, Sungho Won, Jeayeon Park, Yunmi Ko, Youngsu Park, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim Clinical and Molecular Hepatology.2026; 32(1): 339. CrossRef
Integrative Mendelian randomization and experimental validation unveil novel druggable targets in primary biliary cholangitis Yinling Li, Huanhuan Xie, Zhenjie Zhuang, Xin Fang, Wenjun Yang, Yan Luo, Jiangyi Hu, Wei Wang, Haitao Wang, Xiaobing Dou, Junping Shi, Jin Yang European Journal of Pharmacology.2026; 1020: 178775. CrossRef
Integrated Plasma Proteomics and Functional Analyses Reveal Hepatic CDHR2 as a Potential Therapeutic Target in MASLD Yuanping Shi, Qi Huang, Yingning Liu, Xinlei Zhang, Feng Liu, Huiying Rao, Xueyao Han, Linong Ji, Xiantong Zou Diabetes, Obesity and Metabolism.2026; 28(5): 4303. CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach Beom Kyung Kim The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Liver Aging Index: A Noninvasive Score for Liver Biological Aging and Liver‐Related Outcomes in Multicohorts Zhiyu Wu, Shanshan Wu, Shuyao Song, Yating Huang, Canqing Yu, Dianjianyi Sun, Pei Pei, Ling Yang, Yiping Chen, Huaidong Du, Robin Walters, Iona Millwood, Hao Xu, Xiaoming Yang, Junshi Chen, Seung Up Kim, Salvatore Petta, Atsushi Nakajima, Emmanuel Tsochat Aging Cell.2026;[Epub] CrossRef
Correspondence to editorial 2 on “Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis” Hyunjae Shin, Moon Haeng Hur, Yoon Jun Kim Clinical and Molecular Hepatology.2026; 32(3): e381. CrossRef
Proteomic Pathways Linking Type 2 Diabetes Genetic Clusters to Cardiovascular Diseases: A Network Mendelian Randomisation Study Shuang Liao, Gabriel Chun Yin Sung, Yiwen Liang, Chenxi Li, Shiu Lun Au Yeung Diabetes, Obesity and Metabolism.2026; 28(11): 10428. CrossRef
Omics-derived signatures in metabolic dysfunction-associated steatotic liver disease: from molecular characterization to clinical translation Ziyang Qin, Dulguun Juramt, Yuguo Chen, Yunyi Li, Jiaqi Wei, Hongyu Yang, Lanlan Chen, Wei Qiu Frontiers in Medicine.2026;[Epub] CrossRef
Helicobacter pylori, peptic ulcer disease, and colorectal cancer: a prospective study with genome-wide interaction analysis and Mendelian randomization Ziqi Wan, Jiarui Mi, Xiaoyin Bai, Dong Wu, Sunny Hei Wong Infectious Agents and Cancer.2025;[Epub] CrossRef
Evaluating causal protective effect of dual GLP-1R/GIPR agonists on MASLD: A Mendelian randomization and colocalization study Yangke Cai, Siyuan Xie, Liyi Xu, Jiamin Chen, Jianting Cai European Journal of Pharmacology.2025; 1005: 178088. CrossRef
Integrative genome-wide analysis unveils the genetic landscape of gallstone disease and highlights novel loci with therapeutic potential Haotian Chen, Zhengye Liu, Hanze Du, Mixue Zheng, Ziqi Wan, Nan Zhao, Guanqiao Li, Xiaoyin Bai, Dong Wu, Jiarui Mi BMJ Open Gastroenterology.2025; 12(1): e001976. CrossRef
Portal vein thrombosis (PVT) is characterized by the formation of a thrombus (blood clot) within the portal vein system, including main portal vein and its intrahepatic portal vein branches, and may extend to the superior mesenteric vein or splenic vein. The emergence of PVT is linked to diverse risk factors, encompassing liver conditions with cirrhosis, abdominal infections, previous abdominal surgeries, malignancies, inherited or acquired thrombophilias, and systemic hypercoagulable conditions. Recent studies revealed a possible connection between the occurrence of PVT and either contracting corona virus disease 2019 (COVID-19) or receiving a COVID-19 vaccination. Current treatment strategies were primarily based on symptom management, extent, and progression of thrombosis, but their efficacy was inconsistent and suboptimal. Untimely or inadequate treatment can lead to the progression of the thrombus and increase the risk of complications, such as portal hypertension, variceal bleeding, and hepatic decompensation, posing a significant risk to the patient’s life. Thus, early and appropriate initiation of pharmacologic and interventional treatments, as well as more aggressive strategies, is crucial for the management and prevention of PVT progression and recurrence. This review focuses on the literature on the recent advancements in the treatment of PVT using various therapeutic modalities, including anticoagulant therapy, thrombolysis, thrombectomy, interventional therapy and liver transplant in cirrhotic patients. In addition, we discuss pearls and pitfalls of these strategies for PVT, highlighting recent progress, identifying knowledge gaps, and proposing avenues towards precision management.
Citations
Citations to this article as recorded by
Gastrointestinal bleeding risk in cirrhotic portal vein thrombosis: focus on thrombus extension to superior mesenteric vein Sa Lv, Hui Feng, Tianjiao Xu, Hua Tian, Haibo Wang, Dongze Li, Shaoli You, Bing Zhu BMC Gastroenterology.2026;[Epub] CrossRef
Letter: Beyond Survival Benefit in CHANCE2311—Important Considerations in the Interpretation of TACE Combined With Immunotherapy in Advanced HCC Yinghan Chen, Caiyun Lu, Yucheng Xu, Zhidong Zang Alimentary Pharmacology & Therapeutics.2026; 64(5): 701. CrossRef
Risk factors and predictive model for transjugular intrahepatic portosystemic shunt dysfunction in cirrhotic patients Yongbing Zhao, Tingwei Xiong, Sijie Hu, Hao Zhou, En Liu, Zhengguo Xu, Rui Xie European Journal of Gastroenterology & Hepatology.2026; 38(8): 977. CrossRef
Trends in MASLD-related cirrhosis and liver cancer across diverse populations, 2010–2023 Jialin Wu, Bonan Chen, Fuda Xie, Jiahui Hu, Mingyu Liang, Yang Lyu, Peiyao Yu, Tiejun Feng, Muyang Huang, Canbin Fang, Ka Fai To, Terry Cheuk-Fung Yip, Xingxin Wang, Wei Kang Hepatology International.2026;[Epub] CrossRef
Mechanical Thrombectomy and Shunt Embolization to Manage Gastric Variceal Bleeding with Acute Portal Vein Thrombosis Nikhil Shankar, Avinash Bhat Balekuduru, Indushekar Subbanna, Manoj Kumar Sahu Gastroenterology, Hepatology and Endoscopy Practice.2026; 6(3): 101. CrossRef
Prevention and treatment of portal vein thrombosis in cirrhosis Ke-Ke Jin, Hui-Guo Ding World Chinese Journal of Digestology.2026; 34(9): 675. CrossRef
Acute portal vein thrombosis in an elderly man with
homozygous mutations of plasminogen activator
inhibitor-1 and methylenetetrahydrofolate reductase
genes Junxiu Chen, Haonan Zhao, Shengye Yang, Huiyuan Lu, Xingshun Qi Archives of Medical Science.2025;[Epub] CrossRef
Prediction of bowel resection due to bowel necrosis in recent portal vein thrombosis based on CT presentations and clinical data Junyang Luo, Junwei Chen, Hua Tang, Jialin Wu, Xiaohong Wang, Zaibo Jiang, Jie Qin BMC Gastroenterology.2025;[Epub] CrossRef
Long-term patency of the transjugular intrahepatic portosystemic shunt for portal and superior mesenteric vein thrombosis Junyang Luo, Churen Zhou, Yanyang Zhang, Haofan Wang, Caiyun Lu, Jialin Wu, Jie Qin, Zaibo Jiang, Junwei Chen Thrombosis Journal.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a spectrum of pathology involving fatty liver disease that may progress to fibrosis, cirrhosis, hepatocellular carcinoma, and liver failure. The prevalence of MASLD and metabolic dysfunction-associated steatohepatitis (MASH) continues to increase, mirroring the rise in global prevalence of related comorbidities such as obesity and type 2 diabetes mellitus. Due to the alarming rise of these comorbidities, a greater proportion of the population is at risk for developing MASLD and MASH. As such, there has been a significant effort to develop effective therapies for MASLD and MASH. Recently, the U.S. Food and Drug Administration approved resmetirom, a selective thyroid hormone receptor-beta agonist, as the first treatment for patients with MASH. In India, the Drug Controller General of India approved saroglitazar, a dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist, for the treatment of MASLD. Currently, we have various drug classes, including liver-specific therapies, in Phase 3 development with even more agents earlier in the pipeline. This review will discuss prospective therapies in later stages of development such as thyroid hormone receptor-beta agonists, PPAR agonists, glucagon-like peptide-1 receptor agonists, fibroblast growth factor 21 agonists, and fatty acid synthase inhibitors.
Citations
Citations to this article as recorded by
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities Xiao-Dong Zhou, Qiong-Yue Fan, Christopher D Byrne, Giovanni Targher, Mark D Muthiah, Daniel Q Huang, Qin-Fen Chen, Mazen Noureddin, Wenhao Li, Vlad Ratziu, Rohit Loomba, Sven M Francque, Arun J Sanyal, Ming-Hua Zheng Gut.2026; 75(4): 815. CrossRef
Peroxisome proliferator‑activated receptor α regulates acesulfame‑K‑induced NAFLD via hepatic PLCβ: Foe and friend Peng-Yao Lin, Jia-Rong Xie, Tian-Chen Qian, Shi-Song Wang, Si-Yi Yu, Wen-Bo Shi, Ying Wang, Lu-Ze Cen, Qing-Jing Zhu, Yi-Yang Zheng, Hui Gao, Rong Fang, Zhao-Xia Xia, Ai-Ming Liu, Lei Xu International Journal of Molecular Medicine.2026; 57(4): 1. CrossRef
Reply to correspondence on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study” Xingyu Yao Clinical and Molecular Hepatology.2026; 32(2): e267. CrossRef
Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis Dong Yun Kim, Hyung-Jin Rhee, Beom Kyung Kim Clinical and Translational Gastroenterology.2026; 17(7): e01042. CrossRef
An updated overview of alkaloids for the prevention and treatment of metabolic dysfunction-associated steatotic liver disease Jinguo Wang, Ying Zhang, Shuo Sun, Lanyan Hu, Dong Yang Frontiers in Pharmacology.2026;[Epub] CrossRef
The dynamic spectrum of steatotic liver disease: the global perspective Zobair M. Younossi, Shira Zelber-Sagi, Markos Kalligeros, Dana Ivancovsky Wajcman, Linda Henry, Laura Sol Grinshpan, Mads Israelsen, Luis Antonio Diaz, Jiangao Fan, Marco Arrese, Ajay Duseja, C. Wendy Spearman, Mohamed El-Kassas, Yusuf Yilmaz, Juan Pablo Nature Reviews Gastroenterology & Hepatology.2026; 23(11): 812. CrossRef
LAD-NASH score using multiparametric ultrasound for identification of at-risk MASH: head-to-head comparison with the FAST score Seung-seob Kim, Jae Seung Lee, Min Young Lee, Sunyoung Lee Ultrasonography.2026; 45(5): 439. CrossRef
Lipopolymer Nanoparticle‐Mediated In Vivo CRISPR‐Cas9 Editing of Mrg15 Restores Mitochondrial Mitophagy to Alleviate Metabolic‐Associated Steatohepatitis Zixi Zhang, Jing Liao, Tingfeng Yu, Sijie Chen, Ling Zeng, Guanzi Chen, Qian Shen, Yingsen Tang, Meng Jiang, Jinjin Chen, Lingyun Wang Advanced Healthcare Materials.2026;[Epub] CrossRef
Hepatic Lipid Stress Drives Metabolic Dysfunction‐Associated Steatohepatitis Progression through FTO O‐GlcNAcylation‐Induced m6A Demethylation of HRAS Jia‐Xin Yin, Yan‐Lai Zhang, Qun Liu, Rui Liu, Hai‐Yang Yuan, Sui‐Dan Chen, Ming‐Hua Zheng, Kai Wang, Ni Tang, Ai‐Long Huang Advanced Science.2026;[Epub] CrossRef
Multidimensional regulation of hepatic macrophages in chronic liver disease: from metabolic reprogramming to intercellular and interorgan crosstalk Che Xu, Xin-Yu Zhu, Hai-Na Xie, Jing An, Jun-Feng Zhu, Si-Cheng Gao Frontiers in Immunology.2026;[Epub] CrossRef
Mapping nanodelivery design for liver fibrosis: A mechanism-informed framework for functional integration Hyunjun Moon, Haeju Park, Chan Hyeok Lee, Hyun Jin Kim, Juntaek Oh, Jeong Uk Choi, Jin Hee Na, Sangmin Lee Advanced Drug Delivery Reviews.2026; : 115987. CrossRef
Through the implementation of hepatitis B vaccination and effective antiviral treatment over the past four decades, the hepatitis B surface antigen (HBsAg) seroprevalence of the vaccinated generation dramatically decline. The incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) also decreases. However, the elimination of HBV is still a challenge to achieve. Novel HBV biomarkers, including quantitative HBsAg, hepatitis B virus core-related antigen and HBV RNA are promising in predicting clinical phases, risks of disease progression and HBV functional cure. Current antiviral therapies, nucleoside/nucleotide and pegylated alpha-interferon, effectively decrease HCC incidence in chronic hepatitis B (CHB) patients and minimize the recurrence of HCC in patients receiving curative therapy. Novel agents under development to achieve HBV cure include direct-acting antivirals that target various stages of the HBV lifecycle and host targeting agents that enhance HBV-specific immunity. The action plans for eliminating hepatitis B in the future are universal HBV screening, early and simplified treatment as well as precision lifelong management for CHB patients. This narrative review will summarize and discuss global strategies and initiatives aimed at eliminating HBV infection.
Citations
Citations to this article as recorded by
Natural dehydrocostus lactone-based analogues as new structural PDPK1 allosteric activators against HBV Hang Sun, Yu-Jing Mao, Dan-Yang Zhu, Rui-Xian Xu, Bi-Cheng Zhang, Ying Sang, Yi-Zhi Liu, Yang Feng, Guotai Yang, Hao Chen, Shao-Xing Dai, Min Xu European Journal of Medicinal Chemistry.2027; 321: 119455. CrossRef
Insight into the Biology of Hepatitis B Virus and Recent Therapeutic Approaches Prashant Tiwari, Istuti Saraswat, Jyoti Gupta Current Microbiology.2026;[Epub] CrossRef
Refining surveillance of hepatocellular carcinoma in chronic hepatitis B through biomarker-based risk stratification Tai-Chung Tseng, Shang-Chin Huang, Jia-Horng Kao Hepatology Communications.2026;[Epub] CrossRef
Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications Jiayan Yan, Jiayi Wang, Jian Fan, Xinyi Cui, Yuxi Zhang, Xinrong Yang, Qiang Gao, Zhenbin Ding, Zhaoyou Tang, Jia Fan, Dan G. Duda, Ao Huang, Jian Zhou Portal Hypertension & Cirrhosis.2026; 5(1): 65. CrossRef
Exploration and optimization of indole derivatives as novel anti-HBV agent with potential TLR7-agonistic effect Lihua Yang, Zibin Qiu, Xincheng Li, Jiachen Wei, Yike Ma, Weiqun Yuan, Qiuting Xu, Xiaoke Gu, Jingying Qiu Bioorganic & Medicinal Chemistry.2026; 138: 118662. CrossRef
Hepatitis B in Africa: Progress toward World Health Organization 2030 targets, persistent disparities, and COVID-19 setbacks Kui Wang, Ruchen Zhou Clinical and Molecular Hepatology.2026; 32(2): e211. CrossRef
Zinc finger protein ZBTB7A suppresses hepatitis B virus replication by attenuating FXRα-mediated HBV transcription and lowering covalently closed circular DNA levels Dan Xu, Zhenyu Zhao, Beinu Guo, Zhen Wei, Chen Li, Sichen Luo, Wen Shu, Zhongliang Shen, Mengji Lu, Jiming Zhang, Hecun Zou, Fahong Li, Yong Lin Antiviral Research.2026; 252: 106469. CrossRef
Hepatitis B Research in Peru, 1988–2023: Geographic Inequities, Thematic Gaps, and Misalignment with Disease Burden Jhon Omar Palomino-Tenorio, Obert Marín-Sánchez, Jimmy Ango-Bedriñana, Ruy D. Chacón, Homero Ango-Aguilar Pathogens.2026; 15(7): 708. CrossRef
Supramolecular Self-Assembly of Lycorine with Glycyrrhizic Acid into a Nanodrug for Safe and Sustained Anti-HBV Therapy Hang Sun, Zi-Dong He, Bei-Bei Jia, Bo Yuan, Ling-Chuan Kong, Rui-Xian Xu, Qiong Wang, Wen-Jing Pan, Hao Chen, Shao-Xing Dai, Min Xu ACS Applied Bio Materials.2026; 9(15): 7143. CrossRef
Comparable Predictive Performance of Non‐VCTE–Based Machine Learning Model for HBV‐Infected Hepatocellular Carcinoma Risk Hahn Yi, Hye Won Lee, Jae Il Shin, Hyung Woong Lee, Tae Seop Lim, Beom Kyung Kim, Namkug Kim Journal of Gastroenterology and Hepatology.2026; 41(10): 3199. CrossRef
Decoding sequence recognition code of nucleic acid‐binding proteins of human‐infecting DNA viruses Meifang Tang, Shifei Yang, Haiqian Ma, Ruoying Guo, Jie Chen, Hui Zhang, Jinghan Zhang, Wei Sun, Yun Wei, Ligang Fan, Jian Yan iMeta.2026;[Epub] CrossRef
Renal Safety and Antiviral Effectiveness of Tenofovir Alafenamide Versus Entecavir in Patients With Chronic Hepatitis B and Chronic Kidney Disease: A Real‐World Cohort Study Danfeng Ren, Xiangyun Dang, Shan Fu, Ze Zhang, Tianzhi Ni, Wentao Zhang, Yingren Zhao, Jinfeng Liu Journal of Viral Hepatitis.2026;[Epub] CrossRef
ANTIVIRAL THERAPIES AND PUBLIC HEALTH SURVEILLANCE IN THE TREATMENT OF CHRONIC VIRAL HEPATITIS Tarcila de Brito Lira Dal Monte Gadelha, Bruno Machado Aarão, Fernando Falavigna, Sanderson Breno Palheta Corrêa, Rosangela Maria Pereira Valoes Carvalho, Stefany Nazario dos Santos, Erica Cristina Carvalho, Alexandre Leonel Júnior, Dayane de Castro Lopes International Journal of Health Management Review.2026; 12(3): e691. CrossRef
Reply to JFMA-D-26-02276 Chih-Lin Lin, Jia-Horng Kao Journal of the Formosan Medical Association.2026;[Epub] CrossRef
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2025; 40(11): 2750. CrossRef
Intermediate-stage hepatocellular carcinoma (HCC) encompasses a diverse patient population that requires individualized treatment strategies and a multidisciplinary approach. Recent advancements in systemic therapy have expanded the therapeutic options for intermediate-stage HCC, allowing for combination strategies such as systemic therapy with transarterial chemoembolization (TACE) and upfront systemic therapy for individuals deemed unsuitable for TACE. Additionally, the ongoing development of treatment modalities for intermediate-stage HCC has improved the potential for curative conversion and tumor downstaging. Nevertheless, consensus on the optimal management of intermediate-stage HCC remains limited. Thus, the primary aim of this study was to develop a set of consensus guidelines for the management of intermediate-stage HCC. To address this gap, the Taiwan Liver Cancer Association (TLCA) established a working group to develop a multidisciplinary strategy for managing intermediate-stage HCC. Here, we present eight consensus statements formulated by this expert panel, which outline criteria for TACE unsuitability, treatment recommendations based on TACE eligibility, and considerations for various modalities, including conventional TACE, drug-eluting bead TACE, and transarterial radioembolization, as well as the appropriate timing for initiating systemic therapy to enable curative conversion and downstaging. These statements provide specific, evidence-based recommendations for clinicians, addressing treatment pathways based on TACE eligibility and other key considerations for intermediate-stage HCC management. The development of this consensus guideline is intended to aid clinicians in selecting the most appropriate treatment pathway for intermediate-stage HCC, support personalized treatment planning, and ultimately enhance the feasibility of achieving curative conversion.
Citations
Citations to this article as recorded by
Editorial: Tumour Burden Score and Extrahepatic Progression After TACE—Refining Risk Stratification Beyond the Liver Chien‐Wei Su Alimentary Pharmacology & Therapeutics.2026; 63(9): 1316. CrossRef
Optimal treatment selection for hepatocellular carcinoma in the era of immunotherapy Chen-Ta Chi, Yi-Hsiang Huang Journal of Gastroenterology.2026; 61(8): 1041. CrossRef
Prognostic Benefit of Sequential Locoregional Interventions During First-Line Systemic Therapy for Hepatocellular Carcinoma: Insights from Interaction Analysis of Lenvatinib and Atezolizumab/Bevacizumab Junichi Shindoh, Yusuke Kawamura, Tetsuya Hosaka, Takuma Okada, Satoshi Okubo, Masaru Matsumura, Norio Akuta Annals of Surgical Oncology.2026; 33(10): 8799. CrossRef
Systemic treatment paradigms for unresectable and advanced hepatocellular carcinoma in Europe David J. Pinato, Eleonora Alimenti, Pasquale Lombardi, Juan Vaz, Antonia Digklia, Julien Edeline, Najib Ben Khaled, Emanuela Di Giacomo, Bernhard Scheiner, Jose Presa Ramos, Grainne M. O’Kane, Sarah Cappuyns, Giulia Tesini, Lorenza Rimassa The Lancet Regional Health - Europe.2026; 70: 101839. CrossRef
Real-world outcomes of atezolizumab–bevacizumab and durvalumab–tremelimumab in unresectable hepatocellular carcinoma: a systematic review with covariate-adjusted meta-regression and exploratory machine learning analysis Jongin Lee, Kwon Yong Tak, Hee Sun Cho, Jaejun Lee, Keungmo Yang, Pil Soo Sung, Jeong Won Jang, Ji Won Han Frontiers in Immunology.2026;[Epub] CrossRef
Goal-directed minimally invasive treatment of hepatocellular carcinoma across the disease course: a scenario-based clinical framework Rui Cao, Xiao You, Yuhan Huang, Yu Zhang, Feng Xia, Qi Cheng Mini-invasive Surgery.2026;[Epub] CrossRef
Preoperative radioembolization versus chemoembolization and upfront resection for resectable hepatocellular carcinoma beyond the Milan criteria Jeayeon Park, Gyung Sun Lim, Yunmi Ko, Hyunjae Shin, Moon Haeng Hur, Su Young Hong, Suk Kyun Hong, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, YoungRok Choi, Su Jong Yu, Hyo-Cheol Kim, Kwang-Woong Lee, Jung-Hwan Yoon, Kyung-Suk Suh, Jin Wook Chung, Yoon Jun European Radiology.2026;[Epub] CrossRef
Advances in assessment systems and non-pharmacological intervention strategies for cancer-related fatigue following transarterial chemoembolization in hepatocellular carcinoma: a narrative review Shiying Yang, Xuelei Yao, Yali Ren, Teng Ding, Jiamin Gao, Lin Shentu Supportive Care in Cancer.2026;[Epub] CrossRef
Patterns and Prognostic Stratification of Recurrence after Thermal Ablation in Patients with Hepatocellular Carcinoma Chi-Ping Tan, Teng-Yu Lee, I-Cheng Lee, Kuo-Cheng Wu, Chien-An Liu, Nai-Chi Chiu, Shao-Jung Hsu, Pei-Chang Lee, Chi-Jung Wu, Chen-Ta Chi, Jiing-Chyuan Luo, Ming-Chih Hou, Yi-Hsiang Huang Liver Cancer.2025; : 1. CrossRef
Background/Aims Acute liver failure (ALF) has high mortality predominantly due to compromised immune system and increased vulnerability to bacterial and fungal infections.
Methods Plasma lipidome and fungal peptide-based community (mycobiome) analysis were performed in discovery cohort (ALF=40, healthy=5) and validated in a validation cohort of 230 patients with ALF using high-resolution-mass-spectrometry, artificial neural network (ANN) and machine learning (ML).
Results Untargeted lipidomics identified 2,013 lipids across 8 lipid group. 5 lipid-species—phosphatidylcholine (PC)[15:0/17:0], PC[20:1/14:1], PC[26:4/10:0], PC[32:0] and TG[4:0/10:0/23:6]—significantly differentiated ALF-NS (FC>10, P<0.05, FDR<0.01). Mycobiome alpha/beta diversity was significantly higher and showed 4 phyla and >20 species significantly dysregulated in ALF-NS linked with lipid metabolism, fatty acid elongation in ER, and others (P<0.05). Lipid and mycobiome diversity values in ALF-NS were strongly correlated (r2>0.7, P<0.05). Multi-modular correlation network showed striking associations between lipid, fungal peptide modules, and clinical parameters specific to ALF-NS (P<0.05). Cryptococcus amylolentus CBS6039 and Penicillium oxalicum 1142 directly correlated with phosphatidylcholine, triglycerides, and severity in ALF-NS (r2>0.85, P<0.05). POD-fungus and POD-lipids showed direct association with infection, necrosis, and hepatic encephalopathy (Beta>1.2, P<0.05). POD-lipid (AUC=0.969 and HR=1.99 [1.02–2.04]) superseded POD-fungus and severity indices for early-mortality prediction. Finally, significant increase in PC (15:0/17:0) level showed highest normalized importance, and ANNs and ML predicted early mortality with >95% accuracy, sensitivity, and specificity. Interestingly, fungal surveillance protein Clec7a was significantly downregulated (>2-fold), leading to a notable increase in fungal infection-mediated choline/phosphatidylcholine and associated enzymes (FC>1.5; Kennedy cycle). This contributed to phosphatidic acid-mediated hyper-inflammation in ALF-NS.
Conclusions In ALF, the plasma lipidome and mycobiome are dysregulated. Increased circulating phosphatidylcholine could stratify ALF predisposed to early mortality or require emergency liver transplantation.
Citations
Citations to this article as recorded by
Acute-on-chronic liver failure: pathophysiological mechanisms and clinical management S. K. Sarin, Ashok Choudhury, Anupam Kumar, Nadim Mahmud, G. H. Lee, Qin Ning, Soek-Siam Tan, Kessarin Thanapirom, Vinod Arora, Nobuaki Nakayama, Jun Li, Constantine J. Karvellas Nature Reviews Gastroenterology & Hepatology.2026; 23(5): 411. CrossRef
Plasma lipidomic and fungal signatures predict early mortality in acute liver failure Yu Ji Kim, Jong-Won Kim Clinical and Molecular Hepatology.2026; 32(1): e21. CrossRef
Lipidomic profiles associated with treatment related hepatotoxicity in children with acute lymphoblastic leukemia Emily J. Mason, Jeremy M. Schraw, John P. Woodhouse, M. Monica Gramatges, Kevin J. Williams, Baojiang Chen, Melissa B. Harrell, Olga A. Taylor, Michael E. Scheurer, Philip J. Lupo, Karen R. Rabin, Joanna S. Yi, Van Huynh, Steven D. Mittelman, Etan Orgel, Supportive Care in Cancer.2026;[Epub] CrossRef
The signatures and crosstalk of gut mycobiome, microbiome, and metabolites in drug-induced liver injury Weiyan Huang, Yirui Hu, Zexuan Li, Jiake Che, Shuyan Wang, Ye Yang, Shengqi Yan, Yue Chen, Wenkang Gao, Fuyu Yang, Ting Wei, Kai Liu, Yuanqing Zhu, Yupin Tan, Yue Yang, Xinyang Wang, Yonggang Yuan, Zhuang Cao, Xiaotong Du, Jiahao Liu, Ling Yang, Huikuan C Mycology.2026;[Epub] CrossRef
Impaired fungal surveillance with Kennedy pathway activation drives acute liver failure, validated in preclinical models: Correspondence to letter to the editor on “Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatur Neha Sharma, Sushmita Pandey, Shvetank Sharma, Shiv Kumar Sarin, Jaswinder Singh Maras Clinical and Molecular Hepatology.2026; 32(3): e392. CrossRef
Endogenous phosphatidylcholine 16:0/20:4 increases to promote liver regeneration in hepatectomy Luze Cen, Ying Wang, Jie Yang, Wenbo Shi, Pengyao Lin, Weiqi Zhang, Xiaobo Xiang, Xinchang Gao, Jing Huang, Jiongze Fang, Xi Yu, Manyun Dai, Aiming Liu, Caide Lu iScience.2026; 29(8): 116962. CrossRef
Methodological considerations for lipidomic and fungal peptide-based risk stratification in acute liver failure: Letter to the editor on “Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatures for early mortality in a Hu Fu Clinical and Molecular Hepatology.2026; 32(3): e283. CrossRef
Background/Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) may progress to liver inflammation, fibrosis, cirrhosis and hepatocellular carcinoma. So far, genome-wide association studies explain a small fraction of MASLD heritability.
Methods We sought to identify novel genetic determinants of MASLD by exploring interactions between genetic variants and body mass index (BMI). First, we examined genome-wide interactions with BMI for circulating alanine aminotransferase (ALT) levels using UK Biobank data. For identified loci, we next examined associations with hepatic proton density fat fraction (PDFF) in 35,146 independent UK Biobank participants. Associations with PDFF were replicated in four independent European cohorts, followed by a phenome-wide association study. Finally, we used human liver epigenomic maps and CRISPR/Cas9 experiments in vitro and in vivo to functionally characterize the CYP7A1 locus.
Results Thirteen loci interact with BMI for ALT (P<5E-8), including eight well-known genetic modulators of MASLD. Two loci—UBXN2B/CYP7A1 and GIPR—are additionally associated with PDFF. For the intronic rs34783010 in GIPR, the minor T allele is associated with lower BMI and higher HbA1c and liver triglyceride content in humans. The UBXN2B/CYP7A1 locus is associated with PDFF in four additional European cohorts. Epigenomic data and in vitro experiments in human liver cells prioritise rs10504255 and CYP7A1 as the functional effectors in this locus. Perturbation of CYP7A1 orthologues using CRISPR/Cas9 results in less liver fat in 10-day-old, metabolically challenged zebrafish larvae.
Conclusions A genome-wide single nucleotide polymorphism×BMI design fuelled identification of two MASLD genes: CYP7A1 and GIPR.
Citations
Citations to this article as recorded by
Germline mutations and somatic mosaicism in steatotic liver diseases and related liver carcinogenesis Eric Trépo, Jessica Zucman-Rossi, Jean-Charles Nault Nature Reviews Gastroenterology & Hepatology.2026; 23(6): 493. CrossRef
Genetic risk of steatotic liver disease: Pathogenesis, prognosis, and implications for treatment Julia Kozlitina, Stefano Romeo, Helen H. Hobbs Hepatology.2026;[Epub] CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach Beom Kyung Kim The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Longitudinal changes in fatty liver index, genetic susceptibility, and incident atrial fibrillation Siyang Liu, Houde He, Hualan Chen, Hualin Duan, Ying Sun, Dan Deng, Zihao Gui, Lan Liu, Ningjian Wang, Jie Shen, Heng Wan Clinica Chimica Acta.2026; 589: 121028. CrossRef
Mapping the genomic landscape of MASLD: A framework for molecular subtyping and precision hepatology Carlos José Pirola, Silvia Sookoian Med.2026; 7(6): 101131. CrossRef
Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis Dong Yun Kim, Hyung-Jin Rhee, Beom Kyung Kim Clinical and Translational Gastroenterology.2026; 17(7): e01042. CrossRef
Molecular Mechanisms Associated with Metabolic Dysfunction: Contributions of Nutritional Genomics Natália Ellen Delmicon, Nathália dos Reis Franco, Giovanna Cavanha Corsi, Roberta Mi Kyong Kim Cho, Helen Cristina Vidal, Marcelo Macedo Rogero Metabolites.2026; 16(7): 501. CrossRef
Cardiovascular and hepatic outcomes: prognostic differences across MASLD-MetALD-ALD continuum Han Ah Lee, Gi-Ae Kim, Won Kim Clinical and Molecular Hepatology.2026; 32(Suppl): e2026.0367. CrossRef
Genome-wide analyses identify 60 loci associated with liver triglyceride content Oveis Jamialahmadi, Shahir Mowlaei, Kyla Z. Gelev, Rosellina M. Mancina, Valentina Flagiello, Julia Kozlitina, Päivi Pajukanta, Luca Valenti, Stefano Romeo Nature Genetics.2026; 58(11): 2772. CrossRef
GLP1R and GIPR gene sequencing for glycemic response to DPP-4 inhibitors in T2DM patients Kübra Çiğdem Pekkoç Uyanık, Zeynep Gizem Todurga Seven, Hülya Irmak Aksan, Erhan Raşit Agay, Sibel Özyazgan Frontiers in Life Sciences and Related Technologies.2026; 7: 140. CrossRef
Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism Rosellina M. Mancina, Luca Valenti, Stefano Romeo Nature Metabolism.2025; 7(11): 2199. CrossRef
Moana Witte, Carlos Oltmanns, Jan Tauwaldt, Hagen Schmaus, Jasmin Mischke, Gordon Grabert, Mara Bretthauer, Lennart M. Roesner, Thomas Werfel, Katja Deterding, Benjamin Maasoumy, Heiner Wedemeyer, Tim Kacprowski, Anke R.M. Kraft, Markus Cornberg
Clin Mol Hepatol 2025;31(4):1269-1284. Published online June 4, 2025
Background/Aims Hepatitis C virus (HCV) infection remains a global health challenge, leading to chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC). Despite the high efficacy of direct-acting antiviral therapy in achieving sustained virologic response (SVR), concerns persist regarding long-term immune alterations and residual risks, particularly in cirrhotic patients.
Methods This study investigates 75 soluble immune mediator (SIM) profiles in 102 chronic HCV patients, stratified by cirrhosis status, at therapy initiation, end of treatment, and long-term follow-up (median 96 weeks). Findings were compared with 51 matched healthy controls and validated in an independent cohort of 47 cirrhotic patients, 17 of whom developed HCC.
Results We observed significant SIM alterations at baseline, with cirrhotic patients displaying a more profoundly dysregulated inflammatory milieu. Despite an overall decline in inflammatory markers following SVR, persistent alterations were evident, particularly in cirrhotic patients. Notably, those with liver stiffness exceeding 14 kPa exhibited sustained inflammatory dysregulation, correlating with liver elastography values. Key SIM such as interleukin (IL)-6, IL-8, urokinase plasminogen activator, and hepatocellular growth factor remained elevated and were associated with HCC development. Network analysis highlighted their roles in liver fibrosis, regeneration, and carcinogenesis.
Conclusions These findings underscore the importance of early antiviral intervention to prevent cirrhosis-related sequelae. Future studies should explore the mechanistic pathways linking chronic inflammation, fibrosis, and oncogenesis to identify predictive biomarkers and novel therapeutic targets. Addressing persistent immune alterations post-HCV clearance may improve long-term outcomes, particularly in patients with advanced liver disease.
Citations
Citations to this article as recorded by
Gut microbiota–immunity cascade in hepatocellular carcinoma: mechanisms and therapeutic opportunities Jihao Yang, Yishuang Dai, Jia Li Oncology Reviews.2026;[Epub] CrossRef
Hepatitis C elimination: is it time to redefine the goals? Yasser Fouad, Ming-Lung Yu, Saeed Hamid, Robert G. Gish, Mohammed Eslam Nature Reviews Gastroenterology & Hepatology.2026; 23(5): 376. CrossRef
Clinical implications of residual changes following HCV clearance: Editorial on “Distinct inflammatory imprint in non-cirrhotic and cirrhotic patients before and after direct-acting antiviral therapy” So-Young Kim, Eui-Cheol Shin Clinical and Molecular Hepatology.2026; 32(2): 935. CrossRef
Isoliensinine targets NPC1 to reprogram lysosomal cholesterol and establish a reversible antiviral state Lingdong Kong, Xin Jia, Meiqi Zhang, Yiying Li, Yansong Gao, Haoran Shi, Qiqi Li, Cuiqin Cheng, Zheng Luo, Min Li, Anlong Xu, Yao Wang Acta Pharmaceutica Sinica B.2026;[Epub] CrossRef
HBV Dominance Is Associated With a Distinct Inflammatory Milieu in HBV/HCV Coinfection Carlos Oltmanns, Moana Witte, Anika Wranke, Katja Deterding, Heiner Wedemeyer, Christine S. Falk, Anke R. M. Kraft, Steffen B. Wiegand, Markus Cornberg Journal of Viral Hepatitis.2025;[Epub] CrossRef
IFNL4-rs12979860 CC genotype predisposes to accelerated terminal exhaustion and senescence in HIV/HCV-chronic infection Sonia Arca-Lafuente, Violeta Lara-Aguilar, Manuel Llamas-Adán, Sergio Grande-García, Andrés Deza de la Casa, Luz Martín-Carbonero, Pablo Ryan, Ignacio de los Santos, Mariano Matarranz, Mª Ángeles Jiménez-Sousa, Amanda Fernández-Rodríguez, Verónica Briz Journal of Translational Medicine.2025;[Epub] CrossRef
Dong Wook Kim, Won Chang, So Yeon Kim, Young-Suk Lim, Jonggi Choi, Jungheum Cho, Jin-Wook Kim, Jai Young Cho, Sun Kyung Jeon, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Kyung-Suk Suh, Kwang-Woong Lee, Dong Ho Lee
Clin Mol Hepatol 2025;31(4):1285-1297. Published online June 13, 2025
Background/Aims Hepatocellular carcinoma (HCC) frequently recurs after curative treatment, posing challenges to long-term survival. Although contrast-enhanced multiphasic computed tomography (CECT) is commonly used for detecting recurrence, it is associated with risks such as radiation exposure and contrast agent reactions. This study aimed to compare the diagnostic performance of non-contrast magnetic resonance imaging (NC-MRI) with CECT for detecting recurrent HCC.
Methods In this prospective multicenter intra-individual head-to-head comparison trial (study identifier: NCT05690451, KCT0006395), participants who had undergone curative treatment for HCC and remained recurrence-free for over two years were enrolled. Each participant underwent three follow-up imaging sessions at 2–6-month intervals using both CECT and NC-MRI. The primary outcome was the detection accuracy of each modality, analyzed using the generalized estimating equation analysis. Secondary outcomes included sensitivity and specificity.
Results The study included 203 participants with a total of 528 paired imaging sessions, identifying recurrent HCC in 22 cases (10.8%). Among these, 21 cases involved intrahepatic recurrence with a median tumor size of 1.3 cm, and one case had aortocaval lymph node metastasis. NC-MRI achieved a detection accuracy of 96.6% (196/203), higher than CECT’s 91.6% (186/203) (P=0.006). NC-MRI also showed greater sensitivity (77.3% [17/22] vs. 36.4% [8/22]; P=0.012), while specificity was comparable between NC-MRI and CECT (98.9% [179/181] vs. 98.3% [178/181]; P=0.999).
Conclusions NC-MRI demonstrated higher sensitivity and accuracy compared to CECT in detecting recurrent HCC in patients who had been disease-free for over two years following curative treatment, indicating its potential as a preferred imaging modality for this purpose.
Citations
Citations to this article as recorded by
Non-contrast magnetic resonance imaging outperforms contrast-enhanced computed tomography in preoperative detection of hepatocellular carcinoma: A paired validation study Laizhu Zhang, Weiwei Zong, Jialin Gao, Huan Li, Leizhou Xia, Xiaoli Mai, Jun Chen, Binghua Li, Decai Yu Clinical and Molecular Hepatology.2026; 32(1): e34. CrossRef
Updates in Abbreviated MRI‐Based HCC Surveillance Hyo Jung Park, So Yeon Kim, Young‐Suk Lim Journal of Gastroenterology and Hepatology.2026; 41(3): 914. CrossRef
Moving beyond Ultrasound for Hepatocellular Carcinoma Surveillance in High-Risk Patients with Chronic Hepatitis B Hae Lim Lee Gut and Liver.2026; 20(2): 174. CrossRef
Correspondence to editorial on “Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to contrast-enhanced computed tomography” Dong Ho Lee Clinical and Molecular Hepatology.2026; 32(2): e221. CrossRef
Correspondence to letter to the editor on “Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to contrast-enhanced computed tomography” Dong Ho Lee Clinical and Molecular Hepatology.2026; 32(2): e251. CrossRef
Beyond diagnostic accuracy: Economic and clinical considerations for NC-MRI in late HCC recurrence surveillance: Letter to the editor on “Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treat Qi-Feng Chen, Sui-Xing Zhong, Ming Zhao Clinical and Molecular Hepatology.2026; 32(2): e175. CrossRef
Interreader Agreement for Individual Ancillary Features in LI-RADS CT/MRI Version 2018: A Systematic Review and Meta-Analysis Yong Jun Jung, Sang Hyun Choi, Subin Heo, Dong Hwan Kim, Suk Kim, Seung Baek Hong American Journal of Roentgenology.2026;[Epub] CrossRef
HCC surveillance after curative treatment: A new frontier for abbreviated MRI: Editorial on “Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to Hyungjin Rhee, Jin-Young Choi Clinical and Molecular Hepatology.2026; 32(2): 939. CrossRef
Revisiting the role of non-contrast MRI in recurrent HCC: Bridging diagnostic performance and real-world applicability: Letter to the editor on “Non-contrast MRI for detection of late recurrent hepatocellular carcinoma after curative treatment: A prospect Lu Sun, Xin Zhang Clinical and Molecular Hepatology.2026; 32(2): e172. CrossRef
Multicentre prospective trial of abbreviated MRI using gadoxetic acid versus CT for detection of late recurrent HCC (AMRICT): study protocol Hyo Jung Park, Dong Ho Lee, Won Chang, Hae Young Kim, Dong Hwan Kim, Won-Mook Choi, Sung Won Chung, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Han Chu Lee, Young-Suk Lim, Seon-Ok Kim, Amit G Singal, So Yeon Kim BMJ Open.2026; 16(4): e116809. CrossRef
The Use of Non‐Contrast Abbreviated MRI for the Detection of Recurrent Hepatocellular Carcinoma in Postoperative Surveillance Jianwei Chen, Yuemin Zhu, Dechun Zheng, Liting Wen, Juyi Wu, Qiuyuan Yue, Zhuting Fang Journal of Magnetic Resonance Imaging.2026; 64(3): 722. CrossRef
Performance of ASAP, LG2m, and GP73 for HCC Detection in Patients with Cirrhosis Mohammad Jarrah, Mohammed Al-Hasan, Mariadelcarmen Yanez, Maria V. Yow, Eunice Amador, Diya Kar, Fouzia Ahmed, Nicole E. Rich, Sneha Deodhar, Jenna Bedrava, Claire Chen, Amit G. Singal Cancers.2026; 18(16): 2711. CrossRef
Visualization quality and effectiveness of noncontrast-abbreviated magnetic resonance imaging for hepatocellular carcinoma surveillance in cirrhotic patients with ultrasound visualization score C Hyun Kyung Yang, Sunyoung Lee, Min Young Lee, Boryeong Jeong, Eunju Kim, Jeong Hee Yoon European Radiology.2026;[Epub] CrossRef
Performance of GAAD and GALAD Biomarker Panels for HCC Detection in Patients with MASLD or ALD Cirrhosis Mohammad Jarrah, Sneha Deodhar, Lisa Quirk, Mohammed Al-Hasan, Ashish Sharma, Guruveer Bhamra, Julia Terrell, Fasiha Kanwal, Yujin Hoshida, Nicole E. Rich, Purva Gopal, Amit G. Singal Cancers.2025; 17(23): 3835. CrossRef
Background/Aims Hepatitis B virus (HBV) mother-to-child transmission (MTCT) remains a global health concern, with over 90% of perinatal infections leading to chronic HBV. To evaluate long-term trends in MTCT rates and associated factors within Korea’s national program.
Methods Population-based cohort study using linked data from the Perinatal Hepatitis B Prevention Program (PHBPP) and National Health Insurance Service in Korea. The study included HBsAg-positive mother-infant pairs with post-vaccination serologic results from 2002 to 2021.
Results Among the 154,478 mother-infant pairs, the overall MTCT rate after prophylaxis was 2.3%. Antiviral use lowered MTCT rates (0.9% vs. 2.4%) particularly in HBeAg-positivity (1.0% vs. 5.9%; adjusted odds ratio [aOR] 0.21; 95% confidence interval [CI] 0.14–0.32). Lower MTCT rates were observed for cesarean section vs. vaginal delivery (1.9% vs. 2.6%; aOR 0.78; 95% CI 0.73–0.84) and breastfeeding vs. formula feeding (1.8% vs. 2.8%; aOR 0.65; 95% CI 0.56–0.76). Annual MTCT rates decreased from 3.6% (2002–2005) to 1.3% (2018–2021). Antivirals reduced MTCT rates; initiation at 14–27 weeks (0.39%), or 28–32 weeks (0.44%) vs. ≥33 weeks (1.47%); postpartum continuation (0.55%) vs. antepartum discontinuation (1.44%); use ≥61 days (0.51%) vs. 1–60 days (1.67%). Lower MTCT risk was associated with maternal (old age, high income) and infant (female sex, preterm birth) factors.
Conclusions This comprehensive analysis of the PHBPP in Korea demonstrates that the use of antivirals, breastfeeding, and cesarean section, combined with conventional immunoprophylaxis, has significantly reduced MTCT rates. These results are crucial for global HBV elimination and can help to guide HBV MTCT prevention strategies.
Citations
Citations to this article as recorded by
Redefining MTCT prevention strategies toward HBV elimination: Editorial on “Factors associated with hepatitis B mother-to-child transmission in a national prevention program” Eunho Choi, Ji Hoon Kim, Young-Sun Lee Clinical and Molecular Hepatology.2026; 32(2): 943. CrossRef
Redefining MTCT prevention strategies toward HBV elimination: Correspondence to editorial on “Factors associated with hepatitis B mother-to-child transmission in a national prevention program” Moran Ki, Jong-Hyun Kim Clinical and Molecular Hepatology.2026; 32(2): e224. CrossRef
Breaking the chain of perinatal hepatitis B transmission: Editorial on “Factors associated with hepatitis B mother-to-child transmission in a national prevention program” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(2): 946. CrossRef
Reply to correspondence on “Factors associated with hepatitis B mother-to-child transmission in a national prevention program” Eunho Choi, Ji Hoon Kim, Young-Sun Lee Clinical and Molecular Hepatology.2026; 32(2): e262. CrossRef
Factors influencing breastfeeding failure in mothers with hepatitis B infection: a qualitative study Xin Jiang, Hui Jiang, Rong Huang Frontiers in Nutrition.2026;[Epub] CrossRef
Implementation gaps and policy priorities for viral hepatitis elimination in India Trina Sengupta, Saurav Basu Discover Public Health.2026;[Epub] CrossRef
Predictors of seronegativity to HBV vaccine in infants of HBsAg-positive mothers in a national prevention program Moran Ki, Byung-Woo Kim, Naradi Baduge, Jong-Hyun Kim JHEP Reports.2026; : 102032. CrossRef
Background/Aims The role of reactivation of human cytomegalovirus (HCMV) in determining outcomes of cirrhotic patients with acute decompensation (AD) is unknown. We aimed to investigate HCMV incidence and potential correlation with hepatic outcomes in AD patients.
Methods Two prospective multicentre cohorts with AD patients were investigated. Patients in cohort 1 were recruited from 4 centres, while patients in cohort 2 were randomly selected from a second multicentre cohort. HCMV reactivation was established with quantitative real-time polymerase chain reaction assay in seropositive patients.
Results HCMV reactivation was found in 35 patients from cohort 1 (n=722) and 14 from cohort 2 (n=291), with an incidence of 4.8% in both cohorts. Bacterial infection and liver failure were independently correlated with HCMV reactivation. HCMV reactivation was an independent predictor of 90-day mortality. Among bacterial infection populations in these two cohorts, patients with HCMV reactivation had worse prognosis compared to those without. Incidence of acute-on-chronic liver failure (ACLF) was higher in patients with HCMV reactivation compared to those without and was also independently correlated with development of ACLF. In a total of 49 HCMV reactivation cases, 8 patients were treated with ganciclovir, in whom a significantly lower 90-day mortality compared with those not treated was observed. All 3 patients who underwent liver transplantation with reactivation of HCMV died.
Conclusions In AD patients, HCMV reactivation was common, especially in those with bacterial infection or liver failure, and they were more prone to having ACLF and 90‑day mortality. The data propose the need for active surveillance for HCMV infection in AD patients.
Citations
Citations to this article as recorded by
Human cytomegalovirus reactivation in decompensated cirrhosis: marker of immunosuppression or contributor to severity?: Editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation” Zhujun Cao, Richard Moreau Clinical and Molecular Hepatology.2026; 32(2): 953. CrossRef
Correspondence to editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation” Changze Hong, Jinjun Chen Clinical and Molecular Hepatology.2026; 32(2): e227. CrossRef
Call for preemptive treatment of cytomegalovirus in patients with cirrhosis and acute decompensation: Editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation” Norihiro Imai Clinical and Molecular Hepatology.2026; 32(2): 949. CrossRef
Gestational and Congenital Toxoplasmosis: An Updated Review with Emphasis on High-Prevalence Countries Alan Roberto Hatanaka, Antonio Braga, Evelyn Traina, Larissa Keren de Azevedo Teixeira, Carolina Longo, Pedro Teixeira Castro, Heron Werner, Gustavo Yano Callado, Edward Araujo Júnior Women.2026; 6(3): 43. CrossRef
Background/Aims Excessive lipid accumulation in hepatocytes is a critical cause of metabolic dysfunction-associated steatotic liver disease (MASLD) progression. Ankyrin repeat and SOCS box protein 3 (ASB3) is an E3 ubiquitin ligase that mediates diverse disease processes; however, the direct substrates of ASB3 in lipid metabolism and its role in MASLD remain unexplored.
Methods We generated ASB3 knockout mice fed a high-fat diet to induce MASLD. Oxygen consumption and fatty acid oxidation (FAO) were used to assess lipid metabolism. LC-MS/MS and IP were used to verify the ASB3 target protein. Correlation analysis was conducted on the cohort of MASLD patients vs. the control group.
Results Loss of the ASB3 E3 ubiquitin ligase in hepatocytes strengthens mitochondrial FAO, thereby influencing energy consumption to decrease triglyceride storage and lipid accumulation. Quantitative lysine ubiquitination proteomics revealed that ASB3 directly mediated the ubiquitin levels at two sites (K180 and K639) in carnitine palmitoyl transferase 1A (CPT1A), a rate-limiting enzyme of FAO, to induce CPT1A degradation. Moreover, both constitutive and hepatocyte-specific ASB3 knockout enhance FAO and delay lipid accumulation, liver steatosis, and MASLD progression in a CPT1A-dependent manner. Hepatic ASB3 deficiency also delays fibrosis in MASLD. Analysis of public databases and liver tissue samples from MASLD patients revealed that ASB3 was highly expressed in MASLD patients and was negatively correlated with CPT1A.
Conclusions Our study reveals the key roles of ASB3 in the development of MASLD and suggests a novel therapeutic potential for MASLD.
Citations
Citations to this article as recorded by
Targeting the ASB3-CPT1A axis—a new player in combating metabolic dysfunction-associated steatotic liver disease: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver diseas Yueying Yang, Ying Yang, Yan Lu Clinical and Molecular Hepatology.2026; 32(2): 957. CrossRef
The first genome-wide association study on pediatric obesity in Taiwan Hsin-Ru Wu, Ting-Yuan Liu, Chuan-Mu Chen, Fuu-Jen Tsai Journal of the Formosan Medical Association.2026;[Epub] CrossRef
Correspondence to editorial 1 on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A” Yuli Lin, Dongqin Yang, Zhihao Wu, Ming Guan, Chunhua Song Clinical and Molecular Hepatology.2026; 32(3): e339. CrossRef
Correspondence to editorial 2 on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A” Dongqin Yang, Yuli Lin, Chunhua Song, Ming Guan Clinical and Molecular Hepatology.2026; 32(3): e342. CrossRef
ASB3 degrades the gateway to β-oxidation: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A” Ho Jae Ryu, Ji Su Han, Ja Hyun Koo Clinical and Molecular Hepatology.2026; 32(3): 1379. CrossRef
A multi-herb botanical formula ameliorates diet-induced non-alcoholic fatty liver disease associated with microbiota-dependent metabolic remodeling in mice Xinrui Meng, Fan Wang, Ying Li, Yan Li, Meiping Zhang, Jing Cong Food Research International.2026; 243: 120383. CrossRef
ASB3 limits adipocyte thermogenesis and energy expenditure through p62 ubiquitination Mengyu Shi, Haoye Liu, Zhihao Wu, Linlin Huang, Chunhua Song, Yuli Lin, Dongqin Yang Metabolism.2026; 184: 156756. CrossRef
Transcriptome and 16S rRNA analysis reveal the regulatory mechanisms underlying the differences in fat deposition between distinct broiler breeds Fang Wang, Wei Jing, Yuyang Xue, Shanshan Nan, Jinchao Liang, Cunxi Nie Journal of Advanced Research.2026;[Epub] CrossRef
Background/Aims Prediction of short-term mortality in patients with acute-on-chronic liver failure (ACLF) admitted to the intensive care unit (ICU) may enhance effective management.
Methods To develop, explain, and validate a predictive machine learning (ML) model for short-term mortality in patients with ACLF with two or more organ failures (OFs). Utilizing a large ICU cohort with detailed clinical information, we identified ACLF patients with two or more OFs according to the EASL-CLIF and NACSELD definitions. ML model was developed for each definition to predict 30-day mortality. The Shapley value was estimated to explain the models. Validation and calibration of these models were performed.
Results Of 5,994 patients with cirrhosis admitted to ICU, 1,511 met NACSELD criteria, and 1,692 met EASL-CLIF grade II or higher criteria. The CatBoost ACLF (CBA) model had the greatest accuracy in the NACSELD cohort (area under curve [AUC] of 0.87), while the Random Forest ACLF (RFA) model performed best in the EASL-CLIF cohort (AUC of 0.83). Both models showed robust calibration. The models were explained by SHAP score analysis, yielding a rank list, and the top twelve predictors were selected. Both simplified models demonstrated similar performance (CBA model: AUC 0.89, RFA model: AUC 0.81) and significantly outperformed contemporary scoring systems, including CLIF-C ACLF and MELD 3.0. The models were validated in both internal and external cohorts. A simple-to-use online tool was created to predict mortality rates.
Conclusions We presented explainable, well-validated, and calibrated predictive models for ACLF patients with two or more OFs, which outperformed existing predictive scores.
Citations
Citations to this article as recorded by
Unbiased clustering of acute-on-chronic liver failure patients using machine learning in a real-world ICU cohort Mengyi Zhang, Fanpu Ji, Jian Zu, Yingli He, Tao Chen, Yi Liu, Hirsh D. Trivedi, Ju Dong Yang, Vinay Sundaram, Yuan Wang, Xiaodan Sun, Zhujun Cao, Chun-Ying Wu, Yee Hui Yeo, Rajiv Jalan Nature Communications.2026;[Epub] CrossRef
Systematic evaluation of machine learning models for clinical risk prediction on real-world hospital datasets Qingwen Wu, Ziyou Qi, Qingwei Li, Cuiping Hao, Sujuan Tang iScience.2026; 29(5): 115654. CrossRef
Navigating the therapeutic tightrope: Precision use of plasmapheresis and continuous renal replacement therapy in liver failure Manish Manrai, Aditya V Pachisia, Saurabh Dawra, Siddharth Shukla, Atul A Jha World Journal of Hepatology.2026;[Epub] CrossRef
Beyond the Tipping Point: Advances in the Diagnosis and Management of Acute-on-Chronic Liver Failure and End-Stage Liver Disease Jonathan Soldera Diagnostics.2026; 16(10): 1548. CrossRef
Gut–Liver Axis Failure in Critical Alcohol‐Associated Liver Disease: From ICU Secondary Hits to Microbiome‐Targeted Therapy Yuting Zhang, Yiyu Wang, Yong Yang, Hong Mei, Xinxin Liu, Yuanxiu He, Song Qin, Banghai Feng, Ranjitsinh V. Devkar Mediators of Inflammation.2026;[Epub] CrossRef
A machine learning model for 90-day mortality prediction in hepatitis B virus-related acute-on-chronic liver failure: the pivotal role of CALLY index Yijun Zhang, Chunyan Li, Shaohui Su, Jilin Huang, Siyu Fu, Yong Zhang, Shanhong Tang Frontiers in Medicine.2026;[Epub] CrossRef
Harmonized ACLF prognostication with explainable machine learning models: Traversing from counts to composition: Editorial on “Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ fail Sagnik Biswas, Akash Roy Clinical and Molecular Hepatology.2026; 32(3): 1386. CrossRef
Rethinking ACLF prognosis: Can machine learning outperform conventional scores?: Editorial on “Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ failures” Jung Hee Kim Clinical and Molecular Hepatology.2026; 32(3): 1383. CrossRef
Correspondence to editorial on “Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and two or more organ failures” Mengyi Zhang, Yee Hui Yeo, Jian Zu, Jonel Trebicka, Fanpu Ji Clinical and Molecular Hepatology.2026; 32(3): e346. CrossRef
Metabolomics and Machine Learning Uncover 5′-Methylthioadenosine as a Metabolic Indicator of Mixed-Pattern Drug-Induced Liver Injury Jinghui Zhang, Hongchuan Liu, Qingrong Qiu, Kongcai Zhu, Xian Ding, Rui Zhao, Ting Hu, Zhuoling An Metabolites.2026; 16(9): 614. CrossRef
Dynamic prediction of the development of extrahepatic organ failures in ICU patients with decompensated cirrhosis Yee Hui Yeo, Linjie Que, Mengyi Zhang, Jian Zu, Yuankai Wu, Dian-Jung Chiang, Tao Chen, Yu Shi, Yingli He, Fengping Wu, Feng Han, Qing-Lei Zeng, Yu-Chen Fan, Hirsh D. Trivedi, Xiaogang Xiang, Yadong Wang, Yu Chen, Ju Dong Yang, Jun Li, Rajiv Jalan, Fanpu eGastroenterology.2026; 4(3): e100463. CrossRef
Machine learning model for ACLF risk in decompensated cirrhosis Liwen Chen, Peipei Ren, Yi Kang Frontiers in Medicine.2026;[Epub] CrossRef
Background/Aims Bezafibrate (BZF), a dual peroxisome proliferator-activated receptor/pregnane X receptor agonist, has demonstrated efficacy in combination with ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Although one of the therapeutic effects of BZF is suppression of bile acid synthesis, its specific impact on bile acid synthesis pathways has not been thoroughly explored. This study investigated bile acid profiles, synthesis intermediates, and their associations with liver biochemistries in patients with PBC and PSC, and evaluated the impact of BZF treatment on these associations.
Methods We enrolled 30 patients with PBC, 10 with PSC, and 30 control subjects. We measured total bile acids, bile acid components, plasma levels of 7α-hydroxycholesterol (7α-OH-C), 7α-hydroxy-4-cholesten-3-one (C4), and 27-hydroxycholesterol (27-OH-C) to assess the classic and alternative bile acid synthesis pathways and analyzed the association with liver biochemistries with and without BZF treatment.
Results Total bile acid levels were elevated in PBC and PSC compared to controls, correlating significantly with liver biochemistries. BZF treatment significantly suppressed the classic pathway, as evidenced by reduced 7α-OH-C and C4 levels. However, 27-OH-C levels, possibly reflecting the alternative pathway activity, were not reduced in those with elevated liver biochemistries despite BZF treatment, suggesting incomplete suppression of alternative pathway in patients with suboptimal BZF response.
Conclusions These findings indicate that while BZF effectively suppresses the classic pathway, alternative pathway activity may compromise its therapeutic efficacy in treatment-resistant cases, highlighting the need for novel therapies inhibiting the alternative pathway in patients with inadequate response to BZF.
Citations
Citations to this article as recorded by
The effects of starter feed on intestinal fungi and non-targeted metabolomics of blood in calf yaks Hongzhuang Wang, Duojie Qingni, Qing He, Zhandui Pingcuo, Nan Jiang, Yanbin Zhu, Qiang Zhang, Guifang Liu, Guangming Sun, Yangji Cidan, Faisal Ayub Kiani, Dunzhu Luosang, Wangdui Basang BMC Microbiology.2026;[Epub] CrossRef
Metabolic Signatures in Pericardial Fluid and Serum Are Associated with Long-Term Restenosis After Isolated Coronary Artery Bypass Grafting Xiaozheng Zhou, Lin Zheng, Zhiyong Du, Jiyuan Luo, Kun Hua, Xiubin Yang Journal of Clinical Medicine.2026; 15(9): 3436. CrossRef
The Scientific Basis of Cholestatic Liver Disease and Its Symptom Complex Henry H. Nguyen, Mark G. Swain Clinics in Liver Disease.2026; 30(3): 571. CrossRef